Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Novo Nordisk’s Fiasp Ultra-Fast Acting Insulin Now Available in Japan
February 10, 2020
- Japan Ethical Drug Sales Up 3.7% in December 2019: Crecon
February 10, 2020
- With Orix Deal, Reborn Kobayashi Kako Aims to Become Follow-Up to Big 3 Generic Players
February 7, 2020
- Keytruda’s Global Sales Cross US$10 Billion Mark in 2019, Tops Opdivo’s Including Asia
February 7, 2020
- Nesp’s Biosame Switches Rapid but Expected: Kyowa Kirin President
February 7, 2020
- Keytruda Stays Atop Encise’s January Drug Ranking
February 7, 2020
- Zeria Licenses Acofide to Spanish Pharma in 13 Latin American Countries
February 7, 2020
- Kyowa Kirin Nets 12.6% Growth on Positive Sales Overseas; Biosame Trounces Nesp in Q4
February 6, 2020
- Janssen, Mitsubishi Tanabe Expand Copromotion Deal for Stelara
February 6, 2020
- Takeda’s April-Dec. Underlying Sales Sag 1.2% as Hemophilia Meds Falter; Outlook Lifted after Buyout Cost Adjustment
February 5, 2020
- Mitsubishi Tanabe’s April-December Sales Fall 10.5% as Gilenya Feud Continues
February 5, 2020
- Collategene Generates Only 4 Million Yen in 4 Months
February 5, 2020
- Zeria, Kyowa Kirin to End Asacol Collaboration at March-End
February 5, 2020
- Kyowa Hakko Bio Staffers Hid GMP Violations, Fearing Supply Halt: Report
February 4, 2020
- Shionogi Cuts Full-Year Guidance as Xofluza Sales Freefall
February 4, 2020
- Oncolys Hopes for Chugai’s Participation in US Development of Telomelysin: Chief
February 4, 2020
- Bayer, Nippon Kayaku to Copromote Prostate Cancer Med Nubeqa
February 4, 2020
- EU Filing Pulled for Opdivo/Yervoy Combo in Frontline NSCLC
February 4, 2020
- MSD to Transfer Japan Distribution Rights for DPP-4 Inhibitor Marizev to Kissei
February 4, 2020
- Towa Completes Buyout of Pensa Investments
February 4, 2020
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…